Posts tagged SPA
HCW starts Paratek Pharma at buy

H.C. Wainwright has initiated coverage of Paratek Pharmaceuticals (NASDAQ:PRTK) with a “buy” rating and $32 price target. The stock closed at $15.51 on Friday.

Paratek’s lead drug, omadacycline, is a broad-spectrum antibiotic with potent coverage of common bacterial pathogens such as MRSA in both acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP); multi-drug resistant Streptococcus pneumoniae (MDRSP) in CABP; and extended spectrum beta-lactamase-producing Enterobacteriaceae in urinary tract infections (UTI).

Read More
Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients.

OneStep-1 and OneStep-2 are identical Phase 3 trials, with 180 patients per clinical trial. They are being conducted under a SPA with the FDA for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot ulcers.

Read More